Oncolytic Newcastle Disease Virus as Cutting Edge between Tumor and Host

Oncolytic viruses (OVs) replicate selectively in tumor cells and exert anti-tumor cytotoxic activity. Among them, Newcastle Disease Virus (NDV), a bird RNA virus of the paramyxovirus family, appears outstanding. Its anti-tumor effect is based on: (i) oncolytic activity and (ii) immunostimulation. To...

Full description

Bibliographic Details
Main Authors: Philippe Fournier, Volker Schirrmacher
Format: Article
Language:English
Published: MDPI AG 2013-07-01
Series:Biology
Subjects:
Online Access:http://www.mdpi.com/2079-7737/2/3/936
id doaj-2f66eff67bc94334a554a33b9247f589
record_format Article
spelling doaj-2f66eff67bc94334a554a33b9247f5892020-11-25T00:38:13ZengMDPI AGBiology2079-77372013-07-012393697510.3390/biology2030936Oncolytic Newcastle Disease Virus as Cutting Edge between Tumor and HostPhilippe FournierVolker SchirrmacherOncolytic viruses (OVs) replicate selectively in tumor cells and exert anti-tumor cytotoxic activity. Among them, Newcastle Disease Virus (NDV), a bird RNA virus of the paramyxovirus family, appears outstanding. Its anti-tumor effect is based on: (i) oncolytic activity and (ii) immunostimulation. Together these activities facilitate the induction of post-oncolytic adaptive immunity. We will present milestones during the last 60 years of clinical evaluation of this virus. Two main strategies of clinical application were followed using the virus (i) as a virotherapeutic agent, which is applied systemically or (ii) as an immunostimulatory agent combined with tumor cells for vaccination of cancer patients. More recently, a third strategy evolved. It combines the strategies (i) and (ii) and includes also dendritic cells (DCs). The first step involves systemic application of NDV to condition the patient. The second step involves intradermal application of a special DC vaccine pulsed with viral oncolysate. This strategy, called NDV/DC, combines anti-cancer activity (oncolytic virotherapy) and immune-stimulatory properties (oncolytic immunotherapy) with the high potential of DCs (DC therapy) to prime naive T cells. The aim of such treatment is to first prepare the cancer-bearing host for immunocompetence and then to instruct the patient’s immune system with information about tumor-associated antigens (TAAs) of its own tumor together with danger signals derived from virus infection. This multimodal concept should optimize the generation of strong polyclonal T cell reactivity targeted against the patient’s TAAs and lead to the establishment of a long-lasting memory T cell repertoire.http://www.mdpi.com/2079-7737/2/3/936RNA virustumor immunologyimmunotherapy of solid tumorstumor vaccinationvirusdendritic cellsdanger signalsCD8 T-lymphocytes
collection DOAJ
language English
format Article
sources DOAJ
author Philippe Fournier
Volker Schirrmacher
spellingShingle Philippe Fournier
Volker Schirrmacher
Oncolytic Newcastle Disease Virus as Cutting Edge between Tumor and Host
Biology
RNA virus
tumor immunology
immunotherapy of solid tumors
tumor vaccination
virus
dendritic cells
danger signals
CD8 T-lymphocytes
author_facet Philippe Fournier
Volker Schirrmacher
author_sort Philippe Fournier
title Oncolytic Newcastle Disease Virus as Cutting Edge between Tumor and Host
title_short Oncolytic Newcastle Disease Virus as Cutting Edge between Tumor and Host
title_full Oncolytic Newcastle Disease Virus as Cutting Edge between Tumor and Host
title_fullStr Oncolytic Newcastle Disease Virus as Cutting Edge between Tumor and Host
title_full_unstemmed Oncolytic Newcastle Disease Virus as Cutting Edge between Tumor and Host
title_sort oncolytic newcastle disease virus as cutting edge between tumor and host
publisher MDPI AG
series Biology
issn 2079-7737
publishDate 2013-07-01
description Oncolytic viruses (OVs) replicate selectively in tumor cells and exert anti-tumor cytotoxic activity. Among them, Newcastle Disease Virus (NDV), a bird RNA virus of the paramyxovirus family, appears outstanding. Its anti-tumor effect is based on: (i) oncolytic activity and (ii) immunostimulation. Together these activities facilitate the induction of post-oncolytic adaptive immunity. We will present milestones during the last 60 years of clinical evaluation of this virus. Two main strategies of clinical application were followed using the virus (i) as a virotherapeutic agent, which is applied systemically or (ii) as an immunostimulatory agent combined with tumor cells for vaccination of cancer patients. More recently, a third strategy evolved. It combines the strategies (i) and (ii) and includes also dendritic cells (DCs). The first step involves systemic application of NDV to condition the patient. The second step involves intradermal application of a special DC vaccine pulsed with viral oncolysate. This strategy, called NDV/DC, combines anti-cancer activity (oncolytic virotherapy) and immune-stimulatory properties (oncolytic immunotherapy) with the high potential of DCs (DC therapy) to prime naive T cells. The aim of such treatment is to first prepare the cancer-bearing host for immunocompetence and then to instruct the patient’s immune system with information about tumor-associated antigens (TAAs) of its own tumor together with danger signals derived from virus infection. This multimodal concept should optimize the generation of strong polyclonal T cell reactivity targeted against the patient’s TAAs and lead to the establishment of a long-lasting memory T cell repertoire.
topic RNA virus
tumor immunology
immunotherapy of solid tumors
tumor vaccination
virus
dendritic cells
danger signals
CD8 T-lymphocytes
url http://www.mdpi.com/2079-7737/2/3/936
work_keys_str_mv AT philippefournier oncolyticnewcastlediseasevirusascuttingedgebetweentumorandhost
AT volkerschirrmacher oncolyticnewcastlediseasevirusascuttingedgebetweentumorandhost
_version_ 1725298301317677056